Supporting global preclinical drug discovery
iPSC-derived cell models shipped directly from US and European hubs. Discover more.
Human iPSC-derived cells and specialized services
Supporting research & drug discovery with iPSC technology
Axol manufactures cells and provides services across five key areas, neuroscience – including ALS, Alzheimer’s, Huntington’s, Parkinson’s – neuroinflammation, ophthalmology dermatology and cardiovascular.
Axol Bioscience – reliable physiologically relevant iPSC-derived disease models
Axol Bioscience is a leading provider of human induced pluripotent stem cell (iPSC) technologies, specializing in the manufacture of high-performance iPSC-derived cells and the delivery of industry-leading laboratory services. With over a decade of expertise, Axol partners with global pharmaceutical companies, contract research organizations (CROs), biotechnology firms, start-ups, and academic institutions to advance the use of iPSC-based models in drug discovery and disease research.
We operate across five key areas, neuroscience (including ALS, Alzheimer’s, Huntington’s, Parkinson’s, neuroinflammation), ophthalmology (Dry-AMD, ophthal-inflammation), dermatology, and cardiovascular.
Axol offers scalable solutions including iPSC banking, reprogramming, gene editing, cell manufacturing, and quality control. The company is committed to closing the translational gap, developing physiologically relevant in vitro systems that improve consistency and relevance in human disease modeling and compound testing.
Axol is recognized for its scientific excellence, transparent collaboration, and rigorous quality standards, with manufacturing operations certified to ISO 9001:2015.
Products and research services spotlight
iPSC lines from five HD patients and one asymptomatic carrier. CENSOi019-B line (HTT: 14/127 CAG, now CAG143) displays instability in culture and is associated with accelerated disease onset. Striatal neurons derived from this iPSC line provide a model for longitudinal studies of repeat expansion and neurodegeneration and recapitulate key HD phenotypes: CAG instability, neurite pathology, and functional deficits.
Compound efficacy and toxicity testing using human iPSC‑derived retinal organoids, enabling assessment of therapeutic response, mechanism of action. Optimised retinal organoid-based screening systems for retinal toxicity with cell viability (ATP-based assays), morphological assessment, and short- and long-term treatment regimes.
iPSC-derived motor neurons and complex triculture systems provide a physiologically relevant human model for ALS research. These advanced co-culture platforms recapitulate key ALS phenotypes, including motor neuron degeneration, neuroinflammatory responses, and functional deficits, enabling robust compound screening and mechanistic studies to support therapeutic discovery.
